Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

Conduct your own due diligence and consult a financial adviser before making any investment decisions. No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception.

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...

However, China’s influence in global R&D has grown significantly, with expanding clinical trial activity and first-to-market launches. All the news that moves the needle in pharma and biotech ...

While only around 330 Boston-area biotech employees were impacted by layoffs in the first quarter of 2024, that number rose to over 1,810 workers in the second quarter and more than 1,400 people ...

Biotech-Biopharma-Bigpharma，三部曲的发展应该是所有创新药企的终极梦想。但在20年前，这注定只能是一个梦想。 从研发到上市后的商业化，条条道路艰险，没有人能够轻易跨越。所以，授权合作甚至卖身，是绝大部分biotech的归宿。 在这一逻辑下，美国的生物制药 ...

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And readers have made it easy for us—it’s clear what kind of story ...

It’s the holiday season, and what’s better to do than cuddle up in bed and watch a movie? We want to make sure you’re not missing out on some binge-worthy biotech movies this December. So, we have ...

Despite numerous challenges faced by life sciences this year, IPOs have emerged as a resilient force. Image credit: GettyImages/ Daniel Grill. When Australian biotech Telix Pharmaceuticals pulled a ...

It was winner-takes-all in biotech investing in 2024. Larger funds attracted an outsize share of the available investment cash. While many companies struggled, dozens raised at least $100mn.